Labgenomics Co

Labgenomics Co Capital Intensity

The Capital Intensity Ratio of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is 261.05 %. In the previous year, Capital Intensity Ratio was 344.20 % — a change of -24.16% (lower).

Capital Intensity

261.05 %

YoY

-24.16%

Last updated:

Capital Intensity Ratio of Labgenomics Co is 2025 261.05 % . Capital Intensity Ratio of Labgenomics Co was 2024 344.20 % . It decreases by -24.16% lower compared to the previous year.

The Labgenomics Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
171.01 KRW
Jan 1, 2019
149.14 KRW
Jan 1, 2020
91.53 KRW
Jan 1, 2021
100.93 KRW
Jan 1, 2022
173.14 KRW
Jan 1, 2023
441.02 KRW
Jan 1, 2024
344.20 KRW
Jan 1, 2025
261.05 KRW
The Labgenomics Co Capital Intensity history
YEARCapital IntensityYoY
261.05 %-24.16%
344.20 %-21.95%
441.02 %+154.72%
173.14 %+71.54%
100.93 %+10.26%
91.53 %-38.63%
149.14 %-12.79%
171.01 %+6.40%
160.72 %-10.52%
179.62 %+33.72%
134.33 %+0.23%
134.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Capital Intensity Ratio of Labgenomics Co is 261.05 % in 2025.

Capital Intensity Ratio of Labgenomics Co changed from 344.20 % to 261.05 %, representing a -24.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Labgenomics Co

All Key Metrics — Labgenomics Co